BREAKING: Target Test Prep releases Brand New 2026 On Demand GMAT prep course

Redeem

Target Test Prep · GMAT

Choose how you want to prepare

Learn live with an expert or move at your own pace. Every option includes the complete TTP study system.

★★★★★5.0559 reviews
Vote for Target Test Prep, Newsweek Readers’ Choice Awards 2026
NEWSWEEK READERS’ CHOICE 2026

BIG NEWS! Target Test Prep has been nominated, and they’d love your vote!

TTP has worked incredibly hard to build the best test prep experience possible, and winning Newsweek’s 2026 Readers’ Choice Award for Best Test Prep would mean a lot to them. If TTP has helped you, they’d be incredibly grateful for your vote. You can vote once each day through September 9.

Vote for TTP
GMATLiveTeach 7 seats left
Chris Peckover
NEXT LIVE COHORT

Oct 13 to Jan 7, 2027

with Chris Peckover

Schedule
Tue, Thu · 8:00 to 10:00 PM ET
Included
40 live hours + 6 months of GMAT OnDemand
  • Live instruction and real-time questions
  • Class recordings and assigned practice
View class & enroll
Limited cohort · enrollment openTarget Test Prep
EALiveTeach 5 seats left
Logan Thompson
EXECUTIVE ASSESSMENT

Sep 6 to Dec 6, 2026

with Logan Thompson

Schedule
Sun · 9:30 AM to 12:30 PM ET
Included
40 hours of live online classes plus six months of access to the complete TTP EA OnDemand course.
  • 165+ EA Score Guarantee
  • 4,100+ Quant, Verbal, and Integrated Reasoning practice questions
  • 400+ hours of in-depth video lessons
  • 3,000+ step-by-step video solutions
View EA class & enroll
Limited cohort · enrollment openTarget Test Prep
GMATOnDemand Start anytime
SELF-PACED MASTERCLASS

Target Test Prep GMAT OnDemand

Complete access from day one. Study on your schedule.

715+ score guarantee
$0to start then $127/mo
  • Personalized study plan and analytics
  • Thousands of lessons and practice questions

Compare the format, schedule, and included access before enrolling. Prices and seat counts shown reflect the supplied offer details.

Reasearch

Expert replies
Source: — Critical Reasoning |

by raghavsarathy » Thu Jul 30, 2009 9:47 am
IMO - B

Since the competetion has intensified, companies would spend more money

The general narrowing of research targets has resulted in fewer patents.

Since there is a very large market , profits can still be made.
Join the discussion

by madhur_ahuja » Thu Jul 30, 2009 9:52 am
Agree with B, above reasoning.
Join the discussion

by m&m » Thu Jul 30, 2009 11:03 am
A can follow same logic

more stringent gov't regulations require more $/time than in the past.

A and B are on shortlist but would have likely chosen A...

does anyone have OA?


-----------------------------------

UPDATE

I'm jumping ship on A, there are too many assumptions, agree with B
Last edited by m&m on Thu Jul 30, 2009 11:06 am, edited 2 times in total.
Join the discussion

by bignasty666 » Thu Jul 30, 2009 11:03 am
b for me also
Join the discussion

by crackgmat007 » Thu Jul 30, 2009 11:11 am
OA - B
Join the discussion

by ogbeni » Thu Jul 30, 2009 11:30 am
Here's what the trend is (Money Spent = Increase, Drugs Patented = Decrease, Profits = Increased).

Now what conditions would result in the 3 trends?

A.) CORRECT because more stringent government regulations would mean an increase in money spent to be in line with stipulated government codes. Furthermore, more stringent regulations would result in fewer newer drugs getting patented because of the high bar set for any such drug to make it to the market. Finally, a reduction in the number of available drugs means fewer competition, implying more market dominance and higher profits.

B) INCORRECT - Increased competition results in lower prices to consumers because consumers have a wider range of alternatives to choose from {new edit} - looking at this again this is definitely a contender but this really has no bearing on increase in profits because research =|=going to market. Drugs have to pass regulations...this option just doesn't go well with me... :)

C) INCORRECT - C could increase the money spent by meaning additional payments or funding to Universities but the word collaborative connotes 'sharing' so perhaps costs could be underwritten by both Universities and Drug companies (not defininite so scratch that). Also this option has no bearing on a reduction of the number of drugs patented. Universities are not primarily profit making entities so I don't see how getting involved would drive up profits (yes they may make profits but that is not their primary focus). This option doesn't stand on solid ground. ELIMINATE

D) INCORRECT - Duplication has no bearing on money spent. Also has no bearing on a reduction in patents. Duplication would actually reduce profits overall

E) INCORRECT - Actually goes against the 3rd trend. Advertising is a cost, so an increase in advertising could reduce profits
Join the discussion

by ogbeni » Thu Jul 30, 2009 11:35 am
oh well I guess i was wrong :(

Can you post the official explanation so we may learn the line of reasoning?
Join the discussion

by joseph32 » Sun May 15, 2016 8:56 pm
In my opinion B is the most logical one.
Join the discussion